📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
Blog
Protein NMR and its Role in Drug Discovery
We are fortunate at Sygnature Discovery to be one of the few CROs that…
Blog
Alpha Synuclein : An Intriguing Little Protein (Mini Review)
In this mini review we discuss Alpha Synuclein (αSyn), a small, yet curious 140 amino…
Case Studies
Separating Phosphorylation States of a Kinase Using Ion Exchange Chromatography
In this case study we present our ability to express, phosphorylate and separate the native…
Pages
Protein Mass Spectrometry
Technical Notes
LogD7.4
Sygnature Discovery’s LogD7.4 validation confirms the assay’s accuracy and reproducibility across a wide range of compound lipophilicities. Using a classical shake‑flask approach with LC–MS/MS quantification, the method shows strong alignment with literature values and low variability across repeat assays, providing high‑quality lipophilicity data to support confident early‑stage ADME decision‑making.
Technical Notes
ChromLogD
Sygnature Discovery’s ChromLogD validation demonstrates a fast and reliable chromatographic approach for determining lipophilicity, with excellent reproducibility across inter‑ and intra‑assay experiments. The method offers a practical, high‑throughput alternative to shake‑flask assays, supporting confident ADME decision‑making in early drug discovery.
Technical Notes
EPSA
Sygnature Discovery’s EPSA validation demonstrates a fast and reliable SFC‑MS method for estimating exposed polar surface area and understanding how effectively compounds can shield polarity. With optimised chromatography, consistent retention times and strong reproducibility, the assay supports rapid permeability assessment—especially valuable for bRo5 molecules and bifunctional degraders.
Technical Notes
Turbidimetric Kinetic Solubility
Sygnature Discovery’s Turbidimetric Kinetic Solubility validation demonstrates a fast, high‑throughput method for determining aqueous solubility through turbidity measurements in physiological buffer. With consistent performance across controls and a broad set of test compounds, the assay reliably distinguishes high, moderate and low solubility ranges, supporting early decision‑making in in vitro discovery workflows.
Technical Notes
Thermodynamic Solubility
Sygnature Discovery’s thermodynamic solubility validation confirms a robust, equilibrium‑based method for generating high‑confidence solubility data across pH 7.4 buffer and biorelevant media including FaSSIF, FeSSIF and FaSSGF. The assay demonstrates strong reproducibility, good agreement with literature values and clear compound‑dependent solubility shifts, supporting absorption prediction, medicinal chemistry optimisation and formulation strategy development.
Case Studies
Fragment Screening by Crystallography: An Alternative to High Throughput Screening
In this Case Study Helen Gingell and Thirumalai Ulaganathan give an introduction to Fragment based drug discovery (FBDD) with…
Case Studies
Sitryx: Empowering New Ideas
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine. This is where collaborations with expert CROs like Sygnature Discovery can accelerate a drug discovery project towards the clinic.
Case Studies
Corcept Therapeutics: Integrated Drug Discovery Collaboration
Corcept Therapeutics, Menlo Park, CA: Leading cortisol regulation research, targeting Cushing's syndrome & cancers.
Case Studies
CellCentric Lead Optimisation Campaign – CCS1477
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Technical Notes
Chemical Stability
About the Assay Sygnature Discovery’s Chemical Stability assay provides a comprehensive in vitro evaluation of…
Technical Notes
Plasma Stability
About the Assay Sygnature Discovery’s plasma stability assay provides a reliable in‑vitro method for assessing…
Technical Notes
Microsomal Stability
About the Assay Sygnature Discovery’s microsomal metabolic stability assay provides a robust in vitro system…
Technical Notes
Hepatocyte Stability
About the Assay Sygnature Discovery’s hepatocyte metabolic stability assay provides a comprehensive in vitro system…
Technical Notes
Caco-2 Permeability
About the Assay The Caco-2 cell line is derived from human colorectal adenocarcinoma. During extended…
Technical Notes
MDCKII-MDR1
About the Assay The MDCKII–MDR1 (Madin–Darby canine kidney II) is a canine epithelial cell line…
Technical Notes
MDCKII-BCRP
About the Assay The MDCKII–BCRP (Madin–Darby canine kidney II) is a canine epithelial cell line…
Technical Notes
PAMPA Permeability
About the Assay Parallel artificial membrane permeability assay (PAMPA) is an in vitro method to…
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch